Shares of Chimerix (CMRX) touched a new high of $5.15 yesterday, with the company moving one step closer to its goal of accelerating access to the first medicine specific to patients diagnosed with recurrent H3 K27M-mutant diffuse glioma.
H3 K27M-mutant diffuse glioma is a highly aggressive and rare form of brain cancer, classified as WHO Grade 4. It primarily affects children and young adults, with over 2,000 new cases diagnosed annually in the United States. Surgical resection is challenging due to the tumor's location, and current treatment options are limited to radiotherapy, though the tumor almost always recurs. Despite the severity of this condition, there are no approved therapies specifically targeting H3 K27M mutations. The median overall survival for patients is approximately one year from diagnosis, with survival dropping to just 5.1 months from recurrence.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.